Grant Street Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Grant Street Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-601	Closed	-$90K	–	108
2021 Q1	$90K	Hold	601	–	–	0.05%	77
2020 Q4	$91K	Buy	+601	New	+$85.9K	0.05%	56

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Grant Street Asset Management's IBB Position: Q2 2021 in Review

Grant Street Asset Management sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 601 shares — an estimated $90K sold.

Grant Street Asset Management first reported a position in IBB in Q4 2020 and held it in 2 quarters. The position peaked at $91K in Q4 2020. 863 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

Grant Street Asset Management reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
Grant Street Asset Management sold 601 iShares Biotechnology ETF shares in Q2 2021, an estimated $90K.
Grant Street Asset Management first reported a position in iShares Biotechnology ETF in Q4 2020 and held it in 2 quarters.
Grant Street Asset Management's iShares Biotechnology ETF position peaked at $91K in Q4 2020.
863 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on Grant Street Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.